Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MMRF CoMMpass Study Resource Report Resource Website 1+ mentions |
MMRF CoMMpass Study (RRID:SCR_003721) | CoMMpass | consortium, data or information resource, disease-related portal, organization portal, portal, topical portal | A personalized medicine initiative to discover biomarkers that can better define the biological basis of multiple myeloma to help stratify patients. This effort hopes to obtain samples from approximately 1,000 multiple myeloma patients and follow them over time to identify how a patient's genetic profile is related to clinical progression and treatment response. As a partnership between 17 academic centers, 5 pharmaceuticals and the Department of Veterans Affairs, the goal of this eight year study is to create a database that can accelerate future clinical trials and personalized treatment strategies. MMRF's CoMMpass Study has the following goals: * Create a guide to which treatments work best for specific patient subgroups. * Share data with researchers to accelerate drug development for specific subtypes of multiple myeloma patients. In order to facilitate discoveries and development related to targeted therapies, the comprehensive data from CoMMpass is placed in an open-access research portal. The data will be part of the Multiple Myeloma Research Foundation's (MMRF) Personalized Medicine Platform combines CoMMpass data with those collected from MMRF's Genomics Initiative. It is hoped that the longitudinal data, combined with the annotated bio-specimens will help provide insights that can accelerate personalized therapies. | consortium, biomarker, molecular, genetic, blood, cancer, clinical, data sharing |
uses: Multiple Myeloma Genomics Portal is listed by: Consortia-pedia has parent organization: Multiple Myeloma Research Foundation |
United States Department of Veterans Affairs ; Multiple Myeloma Research Foundation |
nlx_157899 | SCR_003721 | Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile, Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Study, Multiple Myeloma Research Foundation (MMRF) - CoMMpass Study | 2026-09-12 12:56:01 | 1 | |||||||
|
Philips Research Resource Report Resource Website |
Philips Research (RRID:SCR_003871) | commercial organization | A global organization that helps Philips introduce innovations that improve people's lives by providing technology options for innovations in the area of health and well-being, targeted at both developed and emerging markets. Positioned at the front-end of the innovation process, they work on everything from spotting trends and ideation to proof of concept and - where needed - first-of-a-kind product development. | health, well-being, technology |
is related to: READNA has parent organization: Philips |
nlx_158235 | SCR_003871 | 2026-09-12 12:56:04 | 0 | ||||||||||
|
MIP-DILI Resource Report Resource Website 1+ mentions |
MIP-DILI (RRID:SCR_003870) | MIP-DILI | consortium, data or information resource, organization portal, portal | Consortium that brings together Europe's top industrial and academic experts to develop new tests that will help researchers detect potential liver toxicity issues much earlier in drug development, saving many patients from the trauma of liver failure. The team aims to deepen the understanding of the science behind drug-induced liver injury, and use that knowledge to overcome the many drawbacks of the tests currently used. A major focus will be on a systematic and evidence-based evaluation of both currently available and new laboratory test systems, including cultures of liver cells in one-dimensional and three dimensional configurations. The project will also develop models that take into account the natural differences between patients. This is important because factors such as certain genes, the liver's immune response, and viral infections have all been associated with an increased risk of DILI. The project will seek to address the current lack of human liver cells available to researchers by using induced pluripotent stem cells (iPSCs) generated from patients who are particularly sensitive to DILI. Another strand of the project will develop computer models to unravel the complex, often inter-related mechanisms behind DILI. Finally, the team will assess how accurate the results of laboratory tests are at predicting actual outcomes in patients. | drug, liver, toxicity test, toxicity, drug development, tool development, liver toxicity, preclinical, model, induced pluripotent stem cell, liver cell, gene, immune response, computer model, outcome |
is listed by: Consortia-pedia is related to: Abbott Diagnostics is related to: Janssen Research and Development is related to: Merck is related to: Orion is related to: University of Liverpool; Liverpool; United Kingdom is related to: University of Freiburg; Baden-Wurttemberg; Germany is related to: German Cancer Research Center is related to: Karolinska Institute; Stockholm; Sweden is related to: University of Rennes 1; Rennes; France is related to: Leiden University; Leiden; Netherlands is related to: Utrecht University; Utrecht; Netherlands is related to: VU University; Amsterdam; Netherlands is related to: Cellartis is related to: CXR Biosciences is related to: Interface Europe is related to: KaLy-Cell is related to: Lhasa Limited is related to: SOLVO Biotechnology has parent organization: Interface Europe |
Innovative Medicines Initiative 115336; EFPIA |
nlx_158195 | SCR_003870 | Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI), Mechanism based Integrated systems for the Prediction of Drug Induced Liver Injury, Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury | 2026-09-12 12:56:04 | 2 | |||||||
|
NEWMEDS Resource Report Resource Website 1+ mentions |
NEWMEDS (RRID:SCR_003872) | NEWMEDS | consortium, data or information resource, organization portal, portal | Consortium that will develop new models and methods to enable novel treatments for schizophrenia and depression including three important missing tools that will facilitate the translation of scientific findings into benefits for patients. The project will focus on developing new animal models which use brain recording and behavioral tests to identify innovative and effective drugs for schizophrenia. The project will develop standardized paradigms, acquisition and analysis techniques to apply brain imaging, especially fMRI and PET imaging to drug development. It will examine how new genetic findings (duplication and deletion or changes in genes) influence the response to various drugs and whether this information can be used to choose the right drug for the right patient. And finally, it will try and develop new approaches for shorter and more efficient trials of new medication - trials that may require fewer patients and give faster results. | drug, biomarker, neuroimaging, drug development, tool development, animal model, fmri, pet, gene, medicine, clinical trial, genetic variation, molecule, model, dna, protein |
is listed by: Consortia-pedia is related to: Abbott Diagnostics is related to: Janssen Research and Development is related to: Orion is related to: Pfizer Animal Genetics is related to: Roche is related to: King's College London; London; United Kingdom is related to: Karolinska Institute; Stockholm; Sweden is related to: University of Cambridge; Cambridge; United Kingdom is related to: Central Institute of Mental Health; Mannheim; Germany is related to: Spanish National Research Council; Madrid; Spain is related to: University of Manchester; Manchester; United Kingdom is related to: Bar-Ilan University; Ramat Gan; Isreal is related to: Psynova Neurotech is related to: deCODE genetics is related to: GABO:mi is related to: AbbVie has parent organization: King's College London; London; United Kingdom is parent organization of: DepressionTools.org Clinical Significance Calculator is parent organization of: Pharmacological Imaging and Pattern Recognition toolbox is parent organization of: DUPCheck |
Innovative Medicines Initiative 115008; EFPIA |
nlx_158196 | SCR_003872 | Novel Methods leading to New Medications in Depression and Schizophrenia, NEWMEDS - Novel Methods leading to New Medications in Depression and Schizophrenia | 2026-09-12 12:56:04 | 6 | |||||||
|
Kinetics for Drug Discovery Resource Report Resource Website 1+ mentions |
Kinetics for Drug Discovery (RRID:SCR_003868) | K4DD | consortium, data or information resource, organization portal, portal | Project whose goal is to improve understanding of how potential drugs bind with their target, and develop methods and tools to allow researchers to study drug-target interactions with greater ease. These tools would help researchers to determine whether a drug candidate is likely to be safe and effective much earlier in the drug development process. The first goal of the team is to enhance understanding of binding kinetics; exactly how do small molecules interact with their targets? Ultimately, the project aims to develop a range of robust techniques, methods and models that could be easily incorporated into the drug development pathway and enable scientists and drug designers worldwide to reliably predict a molecule's kinetic properties (its "kinotype"). This information will allow drug developers to more easily determine the safety and efficacy of a molecule and will weed out ineffective or unsafe molecules earlier in the drug development process. Eventually, the project also hopes to raise awareness of the importance of considering the kinetic aspects of drug-target interactions throughout drug development. | drug-target interaction, drug, drug development, tool development, binding kinetics, small molecule, target, kinotype, kinetics, bind |
is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Leiden University; Leiden; Netherlands is related to: TI Pharma is related to: Imperial College London; London; United Kingdom is related to: Ruhr University Bochum; North Rhine-Westphalia; Germany is related to: University of Vienna; Vienna; Austria is related to: University of Dundee; Scotland; United Kingdom is related to: University of Nottingham; Nottingham; United Kingdom is related to: University of Oxford; Oxford; United Kingdom is related to: European ScreeningPort is related to: Heptares Therapeutics is related to: Heidelberg Institute for Theoretical Studies; Heidelberg; Germany is related to: Sierra Sensors has parent organization: Leiden University; Leiden; Netherlands has parent organization: TI Pharma |
Innovative Medicines Initiative 115366; EFPIA |
nlx_158193 | SCR_003868 | 2026-09-12 12:56:04 | 3 | ||||||||
|
Comprehensive Biomarker Center Resource Report Resource Website |
Comprehensive Biomarker Center (RRID:SCR_003901) | CBC | commercial organization | Commercial organization that discovers, validates & analyzes genomic biomarkers with a focus on body fluid samples. Take advantage of their proven expertise in biomarker signature development and speed up your biomarker studies. | biomarker, clinical research organization, genomic biomarker, genomic, diagnostic, testing, bodily fluid, clinical, dna, rna, dna extraction, rna extraction, microarray, next-generation sequencing, validation, microrna | is related to: READNA | nlx_158236 | SCR_003901 | febit, febit GmbH, Comprehensive Biomarker Center Gmbh | 2026-09-12 12:56:04 | 0 | ||||||||
|
Investigator Databank Resource Report Resource Website |
Investigator Databank (RRID:SCR_003866) | CPID | community building portal, consortium, data or information resource, organization portal, portal | Consortium between several pharmaceutical companies to develop a database that shares clinical trial investigator information that each company has on file to reduce administrative burden for investigators and to increase visibility of qualified investigators to research sponsors. Hosted by a 3rd party, DrugDev, it is the one place where pharmaceutical companies can share investigator and site information and investigators can view, edit, and comment on their own information. Industry members will be able share information from their clinical trial management systems including investigator / site contact details, GCP training records, past trial participation, and recruitment history. Upon investigator opt-in, this information is used by each participating company to identify sites for upcoming studies; to help set recruitment targets and timelines; and to share start-up documents such as CV, GCP, and site profile forms. The Databank has grown to include nearly 180,000 investigators (May 2014) and is already bringing benefits to its member companies in identifying qualified investigators for their studies. It also reported the inclusion of 7,335 protocols and 50K sites, representing a patient population around 1.9M. | drug development, clinical trial, pharmaceutical, investigator, sponsor, data sharing, protocol, drug, tool development, database, people resource |
uses: DrugDev is listed by: Consortia-pedia is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: DrugDev has parent organization: Janssen Research and Development has parent organization: DrugDev |
The community can contribute to this resource | nlx_158192 | SCR_003866 | Cross-Pharmaceutical Investigator Databank | 2026-09-12 12:56:04 | 0 | |||||||
|
Kidney Health Initiative Resource Report Resource Website |
Kidney Health Initiative (RRID:SCR_003869) | KHI | consortium, data or information resource, organization portal, portal | Consortium that brings together the kidney community (patient advocacy groups, industry, government agencies, and professional organizations) to overcome existing challenges, including regulatory and nonregulatory barriers, and optimize the development and safety of products that impact kidney health including drugs, devices, biologics, and food products. The goals of the consortium are to: * Facilitate dialogue and research that informs regulatory processes with regard to the kidney health of patients being treated for kidney-related as well as other diseases. * Assess current medical therapies and diagnostics to identify areas in need of greater innovation and/or better defined regulatory pathways. * Develop innovative and efficient trial designs appropriate to answer the most important questions related to kidney health. * Establish expert consensus around common terminology and key definitions related to kidney health. * Develop approaches to the systematic collection of retrospective or prospective data, such as registries and/or global databases, and establishment of data standards. * Coordinate think tanks, public forums, educational exchanges, and other events to promote discussion and updates on topics in kidney health pertaining to drug, device, biologics, and food product development and evaluation. * Create transparent infrastructure and processes that facilitate collaboration and communication among the greater nephrology community and the FDA, including: * Seek input from all stakeholders (including nephrologists and other health professionals, patient groups, industry, the National Institutes of Health, the Centers for Medicare and Medicaid Services, the Health Resources and Services Administration, and other federal agencies). * Leverage previously conducted and ongoing clinical studies, research infrastructure, and databases. * Create an open and efficient mechanism for encouraging and objectively evaluating potential projects submitted to KHI. * Involve consortium members in the selection and execution of projects. * Establish systems to optimize post-market surveillance of products that affect kidney health, either intentionally or via adverse drug reactions. * Author journal articles and white papers regarding key issues, describing opportunities and challenges and proposing solutions, as well as promoting execution of these solutions. | device development, drug development, tool development, basic research, drug, device, biologics, food product, kidney, data standard, nephrology, safety, innovation, public health |
is listed by: Consortia-pedia is related to: AbbVie is related to: American Association of Kidney Patients is related to: American College of Clinical Pharmacy is related to: American Nephrology Nurses Association is related to: American Society for Apheresis is related to: American Society of Diagnostic and Interventional Nephrology is related to: ASN - American Society of Nephrology is related to: American Society of Pediatric Nephrology is related to: American Society of Transplantation is related to: Anthera Pharmaceuticals is related to: Arbor Research Collaborative for Health is related to: Association for the Advancement of Medical Instrumentation is related to: Baxter is related to: C. R. Bard is related to: ChemoCentryx is related to: ClinMet is related to: University of Oxford; Oxford; United Kingdom is related to: DaVita is related to: Dialysis Patient Citizens is related to: Duke University School of Medicine; North Carolina; USA is related to: ERA-EDTA is related to: FAST BioMedical is related to: Shire is related to: Home Dialyzors United is related to: Hospira is related to: All India Institute of Medical Sciences; New Delhi; India is related to: Juvenile Diabetes Research Foundation is related to: Karolinska Institute; Stockholm; Sweden is related to: University of Washington; Seattle; USA is related to: Mallinckrodt Pharmaceuticals is related to: MediBeacon is related to: Medtronic is related to: National Kidney Foundation is related to: National Renal Administrators Association is related to: NephCure Kidney International is related to: Nephrology Nursing Certification Commission is related to: Nephropath is related to: NxStage Medical is related to: OPKO is related to: Otsuka America Pharmaceutical Inc. is related to: Pfizer Animal Genetics is related to: PKD Foundation is related to: Proteon Therapeutics is related to: Puracath Medical is related to: Quintiles is related to: Reata Pharmaceuticals is related to: Relypsa is related to: Renal Physicians Association is related to: Renal Support Network is related to: Rockwell Medical is related to: St. Marianna University School of Medicine; Kawasaki; Japan is related to: Binding Site is related to: George Institute for Global Health is related to: Thrasos Therapeutics is related to: Vascular Access Society is related to: Vascular Access Society of the Americas is related to: Vascular Therapies is related to: Vasculitis Foundation is related to: W. L. Gore and Associates is related to: U.S. Food and Drug Administration has parent organization: ASN - American Society of Nephrology has parent organization: U.S. Food and Drug Administration has parent organization: Agency for Healthcare Research and Quality has parent organization: Centers for Medicare and Medicaid Services has parent organization: National Institutes of Health |
U.S. Food and Drug Administration ; Membership dues |
nlx_158194 | SCR_003869 | Kidney Health Initiative (KHI) | 2026-09-12 12:56:04 | 0 | |||||||
|
FlexGen Resource Report Resource Website 1+ mentions |
FlexGen (RRID:SCR_003902) | FlexGen | commercial organization | A biotechnology company that has developed technology for synthesizing custom microarrays, the FlexArrayer. Its is a desk-top sized instrument which allows the researcher to generate, in their own laboratory, either a custom oligonucleotide array in a single day or oligonucleotide pool in a few days. Recent developments in synthesis chemistry allows many modifications to be incorporated or for alternative chemistries to be considered., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | biotechnology, microarray, custom oligonucleotide array, oligonucleotide pool, oligonucleotide, gene, probe synthesis, target enrichment, probe design, biomolecule, dna sequencing, oligonucleotide synthesis, re-sequencing | is related to: READNA | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158237 | SCR_003902 | FlexGen B.V. | 2026-09-12 12:56:04 | 6 | |||||||
|
Mosquito Insecticide Resistance Ontology Resource Report Resource Website |
Mosquito Insecticide Resistance Ontology (RRID:SCR_003864) | MIRO | controlled vocabulary, data or information resource, ontology | Application ontology for entities related to insecticide resistance in mosquitos | obo | is listed by: BioPortal | nlx_157486 | SCR_003864 | 2026-09-12 12:56:04 | 0 | |||||||||
|
EU-AIMS Resource Report Resource Website 1+ mentions |
EU-AIMS (RRID:SCR_003861) | EU-AIMS | consortium, data or information resource, organization portal, portal | Consortium aiming to generate tools that will enhance understanding of autism spectrum disorders (ASD) and pave the way for the development of new, safe and effective treatments for use in both children and adults. For example, the team will gather samples from people bearing certain mutations associated with ASD; this will pave the way for the generation of cell lines that can be used to test treatments. Elsewhere, the researchers will advance the use of brain scans as a tool to boost ASD drug discovery and also identify which people with ASD might respond best to a given drug. The project will also create a pan-European network of clinical sites. As well as making it easier to run clinical trials, this network will create an interactive platform for those with ASD and professionals. By the end of the 5 year project they expect to provide novel validated cellular assays, animal models, new fMRI methods with dedicated analysis techniques, new PET radioligands, as well as new genetic and proteomic biomarkers for patient-segmentation or individual response prediction. They will provide a research network that can rapidly test new treatments in man. These tools should provide their EFPIA partners with an added competitive advantage in developing new drugs for ASD. | basic science, tool development, child, adult human, young human, treatment, diagnose, symptom, clinical, cell line, drug, drug discovery, neuroimaging, mutation, clinical trial, medicine |
is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Pfizer Animal Genetics is related to: King's College London; London; United Kingdom is related to: Birkbeck University of London; London; United Kingdom is related to: Central Institute of Mental Health; Mannheim; Germany is related to: CEA; Gif sur Yvette; France is related to: European Molecular Biology Laboratory is related to: University College London; London; United Kingdom is related to: Pasteur Institute is related to: Karolinska Institute; Stockholm; Sweden is related to: Max-Planck-Gesellschaft is related to: Biomedical University Campus of Rome; Rome; Italy is related to: University of Basel; Basel; Switzerland is related to: Ulm University; Baden-Wurttemberg; Germany is related to: University of Cambridge; Cambridge; United Kingdom is related to: Autism Speaks is related to: GABO:mi is related to: deCODE genetics is related to: Noldus has parent organization: Roche |
Innovative Medicines Initiative ; EFPIA |
nlx_158184 | SCR_003861 | European Autism Interventions - A Multicentre Study for Developing New Medications, European Autism Interventions | 2026-09-12 12:56:04 | 2 | |||||||
|
Roslin Cells Resource Report Resource Website 1+ mentions |
Roslin Cells (RRID:SCR_003857) | Roslin Cells | commercial organization | Organization that supplies undifferentiated, clinical grade, human pluripotent stem cell lines to the life science community, and works with academic, clinical and commercial colleagues to enable and facilitate the use of these high grade cells in the development of new reagents, drugs and cellular therapeutics. They also seek to drive the economic development of the stem cell sector in Scotland. Their products can act as a valuable tool in supporting clients' drug discovery, development and clinical research programmes. | pluripotent stem cell, induced pluripotent stem cell, cell therapy, embryonic stem cell line, clinical grade |
is listed by: One Mind Biospecimen Bank Listing is parent organization of: EBiSC |
nlx_158181 | SCR_003857 | Roslin Cells Ltd | 2026-09-12 12:56:04 | 2 | ||||||||
|
EARIP Resource Report Resource Website |
EARIP (RRID:SCR_003854) | EARIP | consortium, data or information resource, organization portal, portal | Consortium that convenes asthma experts from across Europe to define research gaps to reduce the impact of asthma. The project activities range from basic cell science research, to assessing and improving European healthcare systems. Their activities include workshops, prioritization exercises, consensus strategies, and the development and publication of a set of recommendations about what's needed to reduce asthma deaths and hospitalizations. The eventual goal is to have a comprehensive R&D roadmap for asthma. EARIP will target a number of asthma research areas to ensure a comprehensive overview of all current research strategies from across Europe is included in the project road map. These include: * Research into biological targets, aiming to discover new targets and better define the role of existing biological targets * Identify new systems, models and tools for phenotypic stratification * Develop better and more efficient healthcare systems across Europe * Define and develop new diagnostic tools * Assess and improve patient self-management systems and provide suggestions for how these can be developed * Identify how to establish a European Innovation Partnership (EIP) for the management of asthma * Establish a European research network of clinical asthma research facilities | biomarker, biological target, tool development, clinical, basic research |
is listed by: Consortia-pedia is related to: Imperial College London; London; United Kingdom is related to: Karolinska Institute; Stockholm; Sweden is related to: European Federation of Allergy and Airways Diseases Patients Associations is related to: European Lung Foundation is related to: University of Athens; Athens; Greece is related to: University of Southampton; Southampton; United Kingdom is related to: Swiss Institute of Allergy and Asthma Research is related to: University of Lodz; Lodz; Poland has parent organization: Asthma UK |
European Union FP7-Health Programme 602077 | nlx_158171 | SCR_003854 | European Asthma Research and Innovation Partnership, European Asthma Research and Innovation Partnership (EARIP) | 2026-09-12 12:56:04 | 0 | |||||||
|
Mouse Gross Anatomy and Development Ontology Resource Report Resource Website |
Mouse Gross Anatomy and Development Ontology (RRID:SCR_003891) | EMAP | controlled vocabulary, data or information resource, ontology | A structured controlled vocabulary of stage-specific anatomical structures of the mouse (Mus). | obo | is listed by: BioPortal | nlx_157488 | SCR_003891 | 2026-09-12 12:56:04 | 0 | |||||||||
|
Pharmatching Resource Report Resource Website |
Pharmatching (RRID:SCR_003897) | Pharmatching | catalog, commercial organization, community building portal, data or information resource, database, portal, service resource | A matchmaker portal for the pharmaceutical industry worldwide offering a directory and contact platform. This includes a database of ten thousands of profiles of companies offering pharma services as well as a selection of companies including niche providers delivering the service of interest. The platform is used to search for human medicinal products, veterinary medicinal products, cosmeceuticals, nutriceuticals, medical devices, and diagnostics. The company''s platform also enables users to post their service requests, service offers, and APIs/intermediates; and interact with other users. In addition, it offers advice and operational support services for outsourcing and inlicensing processes, such as strategic, scientific, and regulatory advice related to due diligence and decision making of research and development, sourcing, and M and A processes; conduct of third party GMP and pharmacovigilance audits; customized interim solutions; and qualified person functions for GMP and pharmacovigilance. The company also serves various sectors of the life science industry, such as contract manufacture, laboratory investigations and contractual testing, clinical research organizations and pre-clinical research organizations, consulting and legal counseling, logistics and distribution, education, marketing, IT, and investment and financing sectors; and small and medium enterprises/pharma, academic, public institutions, and freelancers. (Bloomberg Businessweek) | outsourcing, pharmaceutical, biotechnology, human medicine, biopharmaceutical, medical device, cosmeceutical, nutraceutical | is related to: ONE Study | The community can contribute to this resource | nlx_158230 | SCR_003897 | Pharmatching.com, Pharmatching GmbH | 2026-09-12 12:56:04 | 0 | |||||||
|
Electro Scientific Industries Resource Report Resource Website |
Electro Scientific Industries (RRID:SCR_003895) | ESI | commercial organization | A high technology company that is a developer and supplier of photonic and laser systems for microelectronics manufacturers. They manufacture a variety of products for testing and repairing equipment, and particularly products designed for use by manufacturers of other high-tech products. These include laser trimming systems. (Adapted from Wikipedia) | microengineering, electronics, semiconductor, testing, repair, laser trimming system, photonic, laser, microelectronics | is related to: ONE Study | nlx_158228 | SCR_003895 | Electro Scientific Industries Inc. | 2026-09-12 12:56:04 | 0 | ||||||||
|
Inserm Transfert Resource Report Resource Website |
Inserm Transfert (RRID:SCR_003808) | commercial organization | A private subsidiary of the French National Institute of the Health and Medical Research (Inserm), dedicated to technology transfer (from invention disclosure to industrial partnership). It manages European and International research projects, supports large scale projects in epidemiology and public health. It has run a proof of concept fund. The company is also committed to seed financing in the biotech sector, through its dedicated seed fund company Inserm Transfert Initiative. www.inserm-transfert.fr | technology transfer, epidemiology, public health |
is related to: AgedBrainSYSBIO has parent organization: National Institute of Health and Medical Research; Rennes; France is parent organization of: AgedBrainSYSBIO |
nlx_158128, grid.14498.30 | https://ror.org/01wftfc57 | SCR_003808 | Inserm-Transfert SA, Inserm Transfert SA | 2026-09-12 12:56:03 | 0 | ||||||||
|
TRANSFoRm Clinical Research Information Model Resource Report Resource Website |
TRANSFoRm Clinical Research Information Model (RRID:SCR_003889) | CRIM | data or information resource, narrative resource, report, standard specification | A clinical research information model for the integration of clinical research covering randomized clinical trials (RCT), case-control studies and database searches into the TRANSFoRm application development. TRANSFoRm clinical research is based on primary care data, clinical data and genetic data stored in databases and electronic health records and employs the principle of reusing primary care data, adapting data collection by patient reported outcomes (PRO) and eSource based Case Report Forms. CRIM was developed using the TRANSFoRm clinical use cases of GORD and Diabetes. Their use case driven approach consisted of three levels of modelling drawing heavily on the clinical research workflow of the use cases. Different available information models were evaluated for their usefulness to represent TRANSFoRm clinical research, including for example CTOM of caBIG, Primary Care Research Object Model (PRCOM) of ePCRN and BRIDG of CDISC. The PCROM model turned out to be the most suitable and it was possible to extend and modify this model with only 12 new information objects, 3 episode of care related objects and 2 areas to satisfy all requirements of the TRANSFoRm research use cases. Now the information model covers Good Clinical Practice (GCP) compliant research, as well as case control studies and database search studies, including the interaction between patient and GP (family doctor) during patient consultation, appointment, screening, patient recruitment and adverse event reporting. | clinical, randomized clinical trial, clinical trial, primary care, genetic, clinical research, electronic health record, model, interoperability |
uses: Clinical Data Interchange Standards Consortium is used by: TRANSFoRm Data Integration Models has parent organization: TRANSFoRm |
nlx_158219 | SCR_003889 | Clinical Research Information Model | 2026-09-12 12:56:04 | 0 | ||||||||
|
Minimum Information About a Simulation Experiment Resource Report Resource Website 1+ mentions |
Minimum Information About a Simulation Experiment (RRID:SCR_003800) | MIASE | data or information resource, narrative resource, standard specification | A set of guidelines (community effort) suitable for use with any structured format for simulation experiments to identify the Minimal Information About a Simulation Experiment necessary to enable the reproducible simulation experiments. The Guidelines list the information that a modeller needs to provide to enable the execution and reproduction of a numerical simulation experiment, derived from a given set of quantitative models. MIASE is designed to help modelers and software tools to exchange their simulation settings and to foster collaboration. In 2011, he MIASE guidelines were accepted by researchers from 19 different institutes. | simulation |
is used by: Simulation Experiment Description Markup Language is listed by: Minimum Information for Biological and Biomedical Investigations |
PMID:21552546 | nlx_158097 | SCR_003800 | MIASE Guidelines | 2026-09-12 12:56:03 | 2 | |||||||
|
TRANSFoRm Resource Report Resource Website 50+ mentions |
TRANSFoRm (RRID:SCR_003888) | TRANSFoRm | consortium, data or information resource, organization portal, portal | Project to develop a ''rapid learning healthcare system'' driven by advanced computational infrastructure that can improve both patient safety and the conduct and volume of clinical research in Europe. Three carefully chosen clinical ''use cases'' will drive, evaluate and validate the approach to the ICT (information and communications technology) challenges. The project will build on existing work at international level in clinical trial information models (BRIDG and PCROM), service-based approaches to semantic interoperability and data standards (ISO11179 and controlled vocabulary), data discovery, machine learning and electronic health records based on open standards (openEHR). TRANSFoRm will extend this work to interact with individual eHR systems as well as operate within the consultation itself providing both diagnostic support and support for the identification and follow up of subjects for research. The approach to system design will be modular and standards-based, providing services via a distributed architecture, and will be tightly linked with the user community. Four years of development and testing will end with a fifth year that will be dedicated to summative validation of the project deliverables in the Primary Care setting. In order to support patient safety in both clinical and research settings, significant ICT challenges need to be overcome in the areas of interoperability, common standards for data integration, data presentation, recording, scalability, and security., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | clinical, interoperability, healthcare system, healthcare, electronic health record, clinical data, metadata standard, aggregator |
has parent organization: King's College London; London; United Kingdom is parent organization of: TRANSFoRm Clinical Data Integration Model is parent organization of: TRANSFoRm Clinical Research Information Model is parent organization of: TRANSFoRm Data Integration Models |
European Union FP7 247787 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158218 | SCR_003888 | Translational Research and Patient Safety In Europe | 2026-09-12 12:56:04 | 60 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant U24DK097771.
Email: info_at_ dknet.org
